Poseida Therapeutics Inc Ordinary Shares PSTX
News
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
Poseida Therapeutics to Present at Upcoming Investor Conferences
Poseida Rises After Reporting Smaller-Than-Seen Loss, Partnership Progress
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment